Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis

IMPORTANCE: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. OBJECTIVE: To evaluate clinical effectiveness and reasons for discontinuation of dupilumab treatment in children, adults, and older adults with AD with up to 5...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of dermatology (1960) 2024-10, Vol.160 (10), p.1044-1055
Hauptverfasser:	Boesjes, Celeste M, Kamphuis, Esmé, de Graaf, Marlies, Spekhorst, Lotte S, Haeck, Inge, van der Gang, Lian F, Loman, Laura, Zuithoff, Nicolaas P. A, Dekkers, Coco, van der Rijst, Lisa P, Romeijn, Geertruida L. E, Oosting, Albert J, Gostynksi, Antoni, van Lynden-van Nes, Anneke M. T, Tupker, Ron A, van Tuyll van Serooskerken, Anne-Moon, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R. H, Christoffers, Wianda A, Stewart, Shiarra M, Kamsteeg, Marijke, Schuttelaar, Marie-Louise A, de Bruin-Weller, Marjolein S
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Age Factors Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Child Clinical outcomes Demographics Dermatitis Dermatitis, Atopic - drug therapy Female Follow-Up Studies Humans Male Medical treatment Middle Aged Monoclonal antibodies Netherlands Prospective Studies Pruritus - drug therapy Pruritus - etiology Registries - statistics & numerical data Severity of Illness Index Time Factors Treatment Outcome Withholding Treatment Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	IMPORTANCE: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. OBJECTIVE: To evaluate clinical effectiveness and reasons for discontinuation of dupilumab treatment in children, adults, and older adults with AD with up to 5 years of treatment in daily practice. DESIGN, SETTING, AND PARTICIPANTS: This prospective multicenter cohort study was conducted using the BioDay registry (4 academic and 10 nonacademic hospitals in the Netherlands) to identify patients with AD of all ages who were treated with dupilumab between October 2017 and December 2022. MAIN OUTCOMES AND MEASURES: Clinical effectiveness was evaluated by the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), and numeric rating scale (NRS) for pruritus, stratified by children (
ISSN:	2168-6068 2168-6084 2168-6084
DOI:	10.1001/jamadermatol.2024.2517